Sanofi posts strong Q3 on sales from Dupixent +61%, Vaccines +8%; guidance raised

• Sanofi (SNY) Q3 results (€):
• Revenues: 9,479M (-0.2%); Pharmaceuticals: 6,361M (-1.1%); Consumer Healthcare: 1,041M (-8.3%); Vaccines: 2,077M (+7.7%), driven by record flu sales partly offset by decline in boosters, travel and Menactra due to COVID-19.
• Key product sales: Dupixent: 918M (+61.1%); Aubagio: 505M (+2.2%); Lantus: 657M (-12.5%); Toujeo: 216M (-0.9%); Lovenox: 365M (+9.3%); Plavix: 205M (-42.4%); Myozyme: 241M (+6.6%); Cerezyme: 162M (-3.6%); Fabrazyme: 204M (+1.0%).
• Specialty Care sales grew 23.8%, driven by strong Dupixent performance and growth in all franchises. General Medicines sales decline 6.4%.
• Net Income: 1,952M (+10.5%); EPS: 1.55 (+9.9%); non-GAAP Net Income: 2,299M (+1.0%); non-GAAP EPS: 1.83 (+0.5%).
• FCF (9 mo.): 5,452M (+39.7%).
• 2020 Guidance: Non-GAAP EPS: to grow between 7-8% from 6-7% at CER.
• The Company is adding seven new Phase 3 programs to oncology and immunology pipelines.
• COVID-19 adjuvanted recombinant protein-based vaccine Phase 1/2 trial fully enrolled.
• https://seekingalpha.com/news/3627944-sanofi-posts-strong-q3-driven-solid-sales-from-dupixentplus-61-and-vaccinesplus-8-guidance